An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.
Autor: | Miyamoto DT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Lee RJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Kalinich M; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., LiCausi JA; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Zheng Y; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Chen T; Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Milner JD; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Emmons E; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Ho U; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Broderick K; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Silva E; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Javaid S; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Kwan TT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Hong X; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Dahl DM; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., McGovern FJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Efstathiou JA; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Smith MR; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Sequist LV; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Kapur R; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Wu CL; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Stott SL; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Center for Engineering in Medicine, Massachusetts General Hospital, Boston, Massachusetts., Ting DT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Giobbie-Hurder A; Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Toner M; Center for Engineering in Medicine, Massachusetts General Hospital, Boston, Massachusetts.; Department of Surgery, Harvard Medical School, Boston, Massachusetts., Maheswaran S; Massachusetts General Hospital Cancer Center, Boston, Massachusetts. dhaber@mgh.harvard.edu maheswaran@helix.mgh.harvard.edu.; Department of Surgery, Harvard Medical School, Boston, Massachusetts., Haber DA; Massachusetts General Hospital Cancer Center, Boston, Massachusetts. dhaber@mgh.harvard.edu maheswaran@helix.mgh.harvard.edu.; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Howard Hughes Medical Institute, Chevy Chase, Maryland. |
---|---|
Jazyk: | angličtina |
Zdroj: | Cancer discovery [Cancer Discov] 2018 Mar; Vol. 8 (3), pp. 288-303. Date of Electronic Publication: 2018 Jan 04. |
DOI: | 10.1158/2159-8290.CD-16-1406 |
Abstrakt: | Blood-based biomarkers are critical in metastatic prostate cancer, where characteristic bone metastases are not readily sampled, and they may enable risk stratification in localized disease. We established a sensitive and high-throughput strategy for analyzing prostate circulating tumor cells (CTC) using microfluidic cell enrichment followed by digital quantitation of prostate-derived transcripts. In a prospective study of 27 patients with metastatic castration-resistant prostate cancer treated with first-line abiraterone, pretreatment elevation of the digital CTC (©2018 American Association for Cancer Research.) |
Databáze: | MEDLINE |
Externí odkaz: |